Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …

LBA7511 Background: INFORM (a phase III, randomized, multicenter, parallel group study;
NCT00770588) investigated the efficacy, safety and tolerability of gefitinib (G) vs. placebo …

Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …

Molecularly targeted therapies have recently expanded the options available for patients
with advanced non-small-cell lung cancer (NSCLC). Two cancer cell pathways in particular …

Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …

In the past decade, molecular-targeted drugs have been focused upon for the treatment of
cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase …

Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …

The Epidermal Growth Factor Receptor (EGFR) family, including EGFR, HER2, HER3, and
HER4, is implicated in the development and progression of cancer, and is expressed in …